Questionnaire survey among ophthalmic allergists on dupilumab-associated ocular surface disease in Japan
Jun Shoji(Nihon University), Nobuyuki Ebihara(Juntendo University Urayasu Hospital), Kaori Yamamoto(Tokyo Medical University), Etsuko Takamura(Tokyo Women's Medical University), Hiroshi Fujishima(Tsurumi University), Tamaki Sumi(Kōchi University), Hiroyuki Yazu(Tsurumi University), Tatsuya Mimura(Tsurumi University), Dai Miyazaki(Tottori University), Tatsuma Kishimoto(Kōchi University), Eisuke Shimizu(Keio University), Ken Fukuda(Kōchi University), Noriko Inada(Saitama Municipal Hospital), Atsuki Fukushima(Augusta University), Kenichi Namba(Hokkaido University), Yoko Kataoka(Osaka Prefectural Medical Center), Akira Hirota(Nihon University), Moe Matsuzawa(Juntendo University), Rumi Adachi(Nihon University), Kazuma Kitsu(Teikyo University), Akira Matsuda(Nihon University), Y. Asada(Juntendo University), Norito Katoh(Kyoto Prefectural University of Medicine), Eiichi Uchio(Fukuoka University)
Cited by 2
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Clinical features and management of cytomegalovirus corneal endotheliitis: analysis of 106 cases from the Japan corneal endotheliitis study
|British Journal of Ophthalmology|2014|189
IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia
|The Journal of Immunology|2008|146
Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
|British Journal of Dermatology|2016|125